Consolidation, or intensification, treatment for acute lymphocytic leukemia ALL is given to prevent leukemia cells from coming back. The consolidation treatment phase begins when the person goes into remission after induction treatment. Consolidation treatment is needed because many people have minimal residual disease MRD after induction therapy.
A new analysis of nearly patients treated with local consolidative therapy LCT for oligometastatic non-small cell lung cancer NSCLC finds that the intensive treatment approach is associated with improved overall survival. LCT, consisting of radiation therapy or surgery, extended median survival by six months for patients diagnosed with three or fewer metastases outside of the lungs. The patients who seem to gain the most benefit are those with more favourable disease characteristics, such as adenocarcinoma, early intrathoracic stage and absence of bone metastases.
This is an open access article distributed under the terms of Creative Commons Attribution License. Advanced breast cancer BC and ovarian cancer OC are two of the most lethal gynaecologic malignancies in developed countries 1. Median survivals are 15 months for metastatic breast cancer 2 and 57 months for stage III ovarian cancer 3.
Historically, treatment for metastatic NSCLC has been palliative chemotherapy 2 which has been shown to modestly prolong 1-year survival in comparison with best supportive care 3. Nowadays, with the advent of more sensitive imaging modalities, improvement in the specificity of radiation therapy delivery, and targeted systemic therapies, many patients with limited metastatic disease are being detected and treated more aggressively, in the absence of randomized, prospective data to support these practices. In patients with metastatic lung cancer, where obstructive or functionally limiting manifestations of disease can reduce performance status and diminish quality of life, there may be a uniquely important role for early enactment of locally directed therapy.
We offer a widget that you can add to your website to let users look up cancer-related terms. Menu Contact Dictionary Search. What Is Cancer?
The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers. Globally, lung cancer is the leading cause of cancer-related mortality.
Consolidation therapy with durvalumab for patients with stage III non-small cell lung cancer represented a cost-effective use of an expensive immunotherapy, according to study published in JAMA Oncology. Durvalumab Imfinzi, AstraZeneca was the first immunotherapy approved for the adjuvant treatment of patients with unresectable stage III NSCLC that did not progress after definitive chemoradiotherapy; however, whether it is cost-effective has been unknown. Criss and colleagues sought to approximate survival and cost outcomes of patients with unresectable stage III NSCLC with no signs of progression after definitive chemoradiotherapy.
Treatment of most patients with acute myeloid leukemia AML is typically divided into 2 chemotherapy chemo phases:. Treatment for AML usually needs to start as quickly as possible after it is diagnosed because it can progress very quickly. Sometimes another type of treatment needs to be started even before the chemo has had a chance to work.
Adding radiation therapy or surgery to systemic therapy for patients with stage IV lung cancer whose cancer has spread to a limited number of sites can significantly extend overall survival, according to new results from a multicenter, randomized, controlled phase II study. The trial was closed prematurely, following accrual and randomization of just 49 patients. The initial results, which also included toxicity data, were for a median follow-up of
By Chase Doyle May 10, Advertisement. A retrospective analysis of nearly patients treated with local consolidative therapy for oligometastatic non—small cell lung cancer NSCLC has found improved overall survival associated with aggressive consolidation. Comprehensive local consolidation was also associated with durable long-term survival, with 1- and 5-year-survival rates approximating those historically observed in earlier stages of disease, the authors of the study reported. As Dr.